NASDAQ:HOWL Werewolf Therapeutics (HOWL) Stock Price, News & Analysis $1.93 -0.12 (-5.85%) (As of 04:32 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Werewolf Therapeutics Stock (NASDAQ:HOWL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Werewolf Therapeutics alerts:Sign Up Key Stats Today's Range$1.91▼$2.1050-Day Range$1.81▼$3.6352-Week Range$1.66▼$8.19Volume563,898 shsAverage Volume376,794 shsMarket Capitalization$86.00 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingBuy Company OverviewWerewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.Read More… Trump’s Back, but DC’s Coming for Your Money! (Ad)Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov Werewolf Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks73rd Percentile Overall ScoreHOWL MarketRank™: Werewolf Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 367th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingWerewolf Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageWerewolf Therapeutics has received no research coverage in the past 90 days.Read more about Werewolf Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Werewolf Therapeutics are expected to decrease in the coming year, from ($1.56) to ($1.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Werewolf Therapeutics is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Werewolf Therapeutics is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWerewolf Therapeutics has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Werewolf Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.76% of the float of Werewolf Therapeutics has been sold short.Short Interest Ratio / Days to CoverWerewolf Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Werewolf Therapeutics has recently increased by 58.51%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldWerewolf Therapeutics does not currently pay a dividend.Dividend GrowthWerewolf Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.76% of the float of Werewolf Therapeutics has been sold short.Short Interest Ratio / Days to CoverWerewolf Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Werewolf Therapeutics has recently increased by 58.51%, indicating that investor sentiment is decreasing significantly. News and Social Media3.9 / 5News Sentiment0.99 News SentimentWerewolf Therapeutics has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Werewolf Therapeutics this week, compared to 2 articles on an average week.Search Interest19 people have searched for HOWL on MarketBeat in the last 30 days. This is an increase of 850% compared to the previous 30 days.MarketBeat Follows12 people have added Werewolf Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Werewolf Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.10% of the stock of Werewolf Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.84% of the stock of Werewolf Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Werewolf Therapeutics' insider trading history. Receive HOWL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HOWL Stock News HeadlinesResearch Analysts Offer Predictions for HOWL FY2024 EarningsNovember 14 at 1:29 AM | americanbankingnews.comPromising Potential of Werewolf Therapeutics’ INDUKINE Platform Despite ChallengesNovember 13 at 2:00 AM | markets.businessinsider.comWhy buying gold might be a mistakeSomething strange just happened with gold. With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years. But for now, I'm not rushing to buy gold. In fact, I'm telling everyone I know to hold off. Because I believe there’s a far better way to play this upcoming surge. It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%. And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock. I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now. Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level.November 14, 2024 | DTI (Ad)Werewolf Therapeutics Advances Innovative Cytokine TherapiesNovember 13 at 2:00 AM | markets.businessinsider.comBuy Rating for Werewolf Therapeutics: Strong Financial Position and Promising PipelineNovember 11 at 12:43 PM | markets.businessinsider.comBuy Recommendation for Werewolf Therapeutics: Promising Developments in WTX-330 Clinical TrialsNovember 9, 2024 | markets.businessinsider.comWerewolf Therapeutics sees cash runway through 2Q26November 8, 2024 | markets.businessinsider.comWerewolf Therapeutics presents preclinical, clinical data on WTX-330November 8, 2024 | markets.businessinsider.comSee More Headlines HOWL Stock Analysis - Frequently Asked Questions How have HOWL shares performed this year? Werewolf Therapeutics' stock was trading at $3.86 at the beginning of the year. Since then, HOWL shares have decreased by 49.2% and is now trading at $1.96. View the best growth stocks for 2024 here. How were Werewolf Therapeutics' earnings last quarter? Werewolf Therapeutics, Inc. (NASDAQ:HOWL) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by $0.06. Werewolf Therapeutics had a negative net margin of 578.80% and a negative trailing twelve-month return on equity of 58.83%. When did Werewolf Therapeutics IPO? Werewolf Therapeutics (HOWL) raised $101 million in an initial public offering on Friday, April 30th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. Who are Werewolf Therapeutics' major shareholders? Werewolf Therapeutics' top institutional shareholders include Walleye Capital LLC (0.24%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Ra Capital Management, LP and Reid Leonard. View institutional ownership trends. How do I buy shares of Werewolf Therapeutics? Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Werewolf Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Werewolf Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL). Company Calendar Last Earnings11/10/2021Today11/14/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/06/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HOWL CUSIPN/A CIK1785530 Webwerewolftx.com Phone617-952-0555FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$15.00 Low Stock Price Target$9.00 Potential Upside/Downside+512.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,370,000.00 Net Margins-578.80% Pretax Margin-1,834.55% Return on Equity-58.83% Return on Assets-38.45% Debt Debt-to-Equity Ratio0.29 Current Ratio10.10 Quick Ratio10.10 Sales & Book Value Annual Sales$19.94 million Price / Sales4.38 Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book0.98Miscellaneous Outstanding Shares44,560,000Free Float35,160,000Market Cap$87.34 million OptionableOptionable Beta0.41 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:HOWL) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.